Gut

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies

Background Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in ...
Gut

Hospitalisation in cirrhosis is linked to distinct gut microbiome structural and functional profiles: a multinational metagenomic study

Background Hospitalisations represent major clinical events in cirrhosis, yet prediction based on clinical variables alone ...
Gut

Metastatic pancreatic cancer: from human disease to preclinical modelling

Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid cancers, portending poor patient outcomes ...
Gut

Global epidemiology of disorders of gut–brain interaction: new insights with Rome V

Following publication of the Rome V diagnostic criteria for disorders of gut–brain interaction (DGBI) earlier this year,1 the ...
Gut

Divergent microbial preludes to necrotising enterocolitis defined by gut phages and bacterial resistomes

Background Translating microbiome correlations into robust predictive features for complex gut disorders remains elusive, ...
Gut

A durably colonising engineered native symbiont enables sustained intestinal delivery for metabolic dysfunction and colitis

Background Engineered bacterial therapeutics represent a promising strategy for sustained intestinal delivery of therapeutic ...
Gut

Coordinated cellular programmes distinguish responses to neoadjuvant PD-L1 blockade and potentiate combinatorial immunotherapy in ESCC

Background Programmed death ligand 1 (PD-L1) blockade offers new therapeutic options for oesophageal squamous cell carcinoma ...
gut.bmj

CTCF-rs705704-SUOX axis is important for the association between hypothyroidism and metabolic dysfunction-associated steatotic liver disease

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
gut.bmj

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

4 Department of Hepatogastroenterology, Hopital Claude Huriez, CHRU Lille, France Correspondence to: Professor J-F Colombel Department of Hepato-Gastroenterology, Hopital Claude Huriez, CHRU de Lille, ...
gut.bmj

Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport

Correspondence to: Dr M Heyman INSERM EMI 0212, Faculté Necker-Enfants Malades, 156 rue de Vaugirard, 75730 Paris, France; heymannecker.fr Background: Probiotic bacteria have a beneficial effect on ...
gut.bmj

Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial

Correspondence to Professor Guy Boeckxstaens, Department of Chronic Diseases, Metabolism, and Ageing, KU Leuven, Leuven, Belgium; guy.boeckxstaens{at}kuleuven.be Objective We evaluated the histamine 1 ...
gut.bmj

ClC-3 chloride channel/antiporter defect contributes to inflammatory bowel disease in humans and mice

3 Gastrointestinal Institute, the 6th Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China Correspondence to Professor Jia-Guo Zhou, Department of Pharmacology, Zhongshan School of ...